Many inhibitors, developed to block KIT and other tyrosine kinase receptors (RTKs), were analyzed in different clinical trials for melanoma such as imatinib, sunitinib, dasatinib, and nilotinib in combination with chemotherapy and immunotherapy [45,46]. The gene discussed is KIT; the disease is melanoma.